Study of the Effects of a Lower Dose of Regorafenib Compared to Standard Dose Regorafenib in Patients with Resistant Metastatic Colorectal Cancer

What we are studying

The purposes of this research study is to: Find out which dose of regorafenib will work better for patients with resistant metastatic colorectal cancer; Find out what effects, good and/or bad, the different dosages of regorafenib have on you and your resistant metastatic colorectal cancer; Find out what effects, good and/or bad clobetasol has on reducing the chance of developing hand-foot skin reactions or treating hand-foot skin reactions after they develop.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Tumor biopsy before starting treatment with regorafenib
  • Second biopsy 2-3 weeks after starting treatment
  • Required research blood tests

What is involved

  • Routine blood tests
  • Urine sample
  • CT scans or MRI’s for tumor measurement
  • Pregnancy test
  • Electrocardiogram (ECG) (this measures how your heart is doing)
  • Required research blood draw
  • Questionnaires
  • Tumor biopsy prior to treatment
  • Second tumor biopsy 2-3 after starting treatment

Compensation

No compensation; Parking validation for research study visits

Contact Information

Study Coordinator
Amy Neal, RN
Email
aneal@wakehealth.edu
Phone
336-713-6912

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.